Menveo Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Menveo market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period was driven by public immunization initiatives, a significant burden of meningococcal disease, robust healthcare infrastructure, international travel requirements, and mandatory military vaccination programs.

The anticipated growth in the forecast period can be attributed to factors such as population increase, rising healthcare awareness, growth in travel activity, expanding school vaccination requirements, and market development in emerging regions. Key trends expected during the forecast period include the rise of combination vaccines, emphasis on booster doses, increasing demand in developing economies, improvements in cold chain logistics, and strategic partnerships for enhanced market penetration.

The rising prevalence of meningitis is expected to drive the growth of the menveo market in the future. Meningitis is an infection that leads to inflammation of the protective membranes (meninges) surrounding the brain and spinal cord. It can be caused by viral, bacterial, or fungal infections. Additionally, factors such as antibiotic resistance, weakened immune systems, and global mobility contribute to the spread of the disease. Menveo, a meningococcal vaccine, helps reduce meningitis prevalence by offering protection against several strains of Neisseria meningitides, a leading cause of bacterial meningitis. Its widespread use in vaccination programs helps prevent outbreaks and reduce disease transmission. For example, in August 2024, the UK Health Security Agency, a government body in the UK, reported that the meningococcal reference unit (MRU) confirmed 396 cases of invasive meningococcal disease (IMD) between 2022 and 2023, a notable rise from 205 cases reported from 2021 to 2022. Therefore, the growing prevalence of meningitis is propelling the expansion of the menveo market.

The global growth of healthcare infrastructure is expected to further boost the menveo market. Healthcare infrastructure refers to the physical and organizational resources, systems, and facilities necessary to provide healthcare services to a population. The expansion is driven by factors such as an aging global population, the rise of chronic diseases, and technological advancements. Menveo, a meningococcal vaccine, protects individuals from invasive meningococcal disease by utilizing healthcare infrastructure through vaccination programs in clinics, hospitals, and public health initiatives. For instance, in September 2024, according to data published by Cross River Therapy, a US-based provider of applied behavior analysis therapy services, the US pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medications in 2021. This spending is projected to increase to $605-$635 billion by 2025. Consequently, the global expansion of healthcare infrastructure is driving the growth of the menveo market.

A key trend in the menveo market is the development of innovative vaccine formulations, such as single-vial, fully liquid formulations, which enhance convenience, improve stability, and simplify vaccine administration. Single-vial, fully liquid formulations refer to pharmaceutical products that are pre-mixed and packaged in a single vial, with the active ingredients already dissolved in a liquid, ready for immediate administration. For instance, in November 2024, GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical company, received approval from the European Commission (EC) for a new version of its meningococcal vaccine, Menveo, for the active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. This new version of the vaccine is licensed for use in children aged two years and older, adolescents, and adults. Notably, the approval includes a new single-vial, fully liquid presentation, which eliminates the need for reconstitution before administration.

The key company operating in the menveo market is GlaxoSmithKline (GSK) Plc.

North America was the largest region in the menveo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in menveo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the menveo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Menveo is a meningococcal vaccine designed to protect against infections caused by neisseria meningitidis. It targets serogroups A, C, W, and Y, which are responsible for meningitis and bloodstream infections. The vaccine is recommended for adolescents, young adults, and individuals at increased risk of meningococcal disease.

The primary types of the menveo vaccine include conjugate vaccines and combination vaccines. A conjugate vaccine links a bacterial protein to a polysaccharide (sugar molecule) to boost the immune response, helping the immune system identify and combat the bacteria more effectively. It is indicated for various applications, such as preventing meningococcal disease, routine immunization, outbreak management, and travel-related vaccination. Menveo is administered to various age groups, including infants and young children, adolescents, adults, and older adults. Key end users include hospitals, vaccination clinics, travel clinics, academic and research institutions, and military and government facilities.

The menveo market research report is one of a series of new reports that provides menveo market statistics, including the menveo industry's global market size, regional shares, competitors with a menveo market share, detailed menveo market segments, market trends and opportunities, and any further data you may need to thrive in the menveo industry. This menveo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The menveo market consists of sales of prefilled syringes, powders for suspension, combination vaccines, booster doses, and single-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.